Drug Profile
Research programme: cardiovascular therapy - Affymetrix/Baylor
Latest Information Update: 30 Aug 2006
Price :
$50
*
At a glance
- Originator Affymetrix; Baylor College of Medicine
- Developer Affymetrix
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 30 Aug 2006 Discontinued - Preclinical for Cardiovascular disorders in USA (unspecified route)
- 28 Oct 2005 ParAllele BioScience has been acquired and merged into Affymetrix
- 22 Sep 2003 Preclinical trials in Cardiovascular disorders in USA (unspecified route)